missing translation for 'onlineSavingsMsg'
Learn More

Novus Biologicals™ MALP-2, TLR6 and TLR2 ligand

Applications: Functional, In vitro assay

Brand:  Novus Biologicals™ NBP2-26219

 View more versions of this product

Product Code. 18709023

  • £571.00 / 50µg

Please to purchase this item. Need a web account? Register with us today!

Explore more special offers
This item is not returnable. View return policy

Description

Description

Specific Activity is approx. 2x10^8units/mg. One unit is defined as the dilution giving half maximal release of nitric oxide from C3H/HeJ mouse peritoneal exudate cells in the standard assay. Immunogen: MALP-2, TLR6 and TLR2 ligand Buffer: 2μg in 20μL of sterile PBS solution containing 2.5% (v/v) 2-propanol, 25mM n-octyl-b-D-glucopyranoside and 1% (wt/v) human serum albumin. Dilution: Functional, In vitro assay MALP-2 was originally isolated from Mycoplasma fermentans. This MALP-2 corresponds to the originally isolated isomer, which expresses potent endotoxin-like activity and approaches in certain experimental systems the toxicity of LPS. MW: 2135.2
Specifications

Specifications

0.1 mg/mL
Store at -20C. Avoid freeze-thaw cycles.
Source: Synthetic Formula: C99H167N19O30S MW: 2135.2 Use in In-Vitro and Functional Assay Reported in Scientific Literature (PMID: 25466255).
Human/Mouse/Avian
C99H167N19O30S
50 μg
MALP-2, TLR6 and TLR2 Ligand
Product Suggestions

Product Suggestions

Videos
SDS
Documents

Documents

Certificates
Special Offers

Special Offers

Product Content Correction

Your input is important to us. Please complete this form to provide feedback related to the content on this product.

Product Title

By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.

Thank You! Your feedback has been submitted. Fisher Scientific is always working to improve our content for you. We appreciate your feedback.